Actively Recruiting
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Led by Peking University Cancer Hospital & Institute · Updated on 2026-03-04
15
Participants Needed
1
Research Sites
283 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
CONDITIONS
Official Title
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged over 18 years old with ECOG performance status 0 or 1
- Diagnosed with solid tumors
- Have at least one measurable target lesion according to RECIST V1.1
- Life expectancy of at least 12 weeks
You will not qualify if you...
- Significant liver or kidney dysfunction
- Pregnant or planning to become pregnant
- Unable to remain still for half an hour
- Refusal to participate in the clinical study
- Claustrophobia or other mental health conditions
- Any condition deemed unsuitable by researchers for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing cancer hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
H
Hua Zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here